The Union Health Ministry has proposed amending the Drugs Rules, 1945 so that a drug's manufacturing licence is suspended immediately once a Government Analyst declares it Not of Standard Quality (NSQ) on assay, dissolution, related substances, impurities or sterility.
At present, suspension or cancellation comes only after procedure including a show-cause notice, during which an NSQ drug can stay in circulation.
A suspension is lifted only after the manufacturer completes a Root Cause Analysis and Corrective and Preventive Action (CAPA), verified by the licensing authority.
Form 13 (the Government Analyst's report) will go to the DCGI, the State/UT licensing authority of the manufacturing site, and the manufacturer and marketer.
A separate draft, G.S.R. 953(E) of 28 October 2026, aligns Schedule M's Grade A microbial limits with WHO TRS No. 1044, Annex 2; comments are invited within 30 days.
National drug regulator under the Directorate General of Health Services, MoHFW: new-drug approvals, clinical trials, import control, central licensing of specified categories
Heads CDSCO; will now receive every NSQ report directly
Statutory body under Section 5 of the 1940 Act; advises Centre and States on technical matters
Advisory committee under Section 7; brings Central and State drug regulators together for uniform enforcement
License most drug manufacturing units; State drug controllers act on NSQ findings in their jurisdiction
Good Manufacturing Practices first placed in Schedule M of the Drugs Rules
Schedule M amended (GMP and requirements of premises, plant and equipment)
WHO publishes TRS No. 1044, Annex 2 — revised GMP for sterile pharmaceutical products
Revised Schedule M notified (G.S.R. 922(E)) to align with WHO GMP; firms above Rs 250 crore turnover given 6 months
G.S.R. 127(E) extends compliance for units with turnover up to Rs 250 crore to 31 December 2025
Draft G.S.R. 953(E) aligns Grade A microbial limits with WHO TRS 1044
An NSQ drug is a genuine product from a licensed maker that fails a prescribed quality test, such as low active content (assay) or poor dissolution. A spurious drug is a fake or misbranded imitation. CDSCO publishes monthly alerts listing both.
Coldrif batch SR-13 tested at 48.6% diethylene glycol against a 0.1% limit and was linked to the deaths of about two dozen children in Chhindwara, Madhya Pradesh. Tamil Nadu first issued a show-cause notice and cancelled Sresan Pharma's licence on 13 October 2025. That gap between finding and action is what this amendment targets.
A day earlier, MoHFW proposed separate Drugs Rules amendments on import gateways and batch release — part of the same regulatory tightening.
GS Paper 2 > Governance > Health > Statutory and Regulatory Bodies
General Awareness > Polity > Acts and Bodies
The Drugs Rules schedule prescribing Good Manufacturing Practices; revised December 2023 to WHO standards.
Corrective and Preventive Action — must follow a Root Cause Analysis before a suspended licence is restored.
Statutory analyst whose Form 13 test report declares a sample of standard quality or not.